News

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

The biosimilar to aflibercept (Eylea) has already received approval in the EU and US

The new formula will help relieve temporary symptoms caused by dryness of the eye.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

Francesco Bandello, MD, FEBO, discusses the Diabetic Eye Conditions Coalition and a five-point call to action

Amniotic membrane tissue offers a number of advantages to patients.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Italian investigators reported that ocular surface conditions such as dry eye disease are key factors in perioperative outcomes, even when patients achieve 20/20 vision

Clinician highlights a novel complication of atropine treatment in a teenage patient.

The imaging system is designed to enable secure, real-time remote monitoring around the clock, from virtually any location.

At the Envision Summit 2025 in San Juan, Puerto Rico, retina program chairs Geeta Lalwani, MD, and Majda Hadziahmetovic, MD, discussed Hadziahmetovic's presentation on deep learning models of neovascular AMD as well as their time at the conference.

This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

Prevent Blindness will be sharing a variety of free educational resources to the public and professionals during the awareness week, which will be held February 24, 2025, through March 2, 2025.

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness.

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

At the Envision Summit 2025 in San Juan, Puerto Rico, Kelly Donovan, MD, talked about her graduate research on the earliest phase of diabetic retinopathy, and trying to understand how hyperglycemia translates into disease.

Voyager DSLT is already available in select markets in the EU and the UK, and reduces the specialised training required with manual selective laser trabeculoplasty

Sexual harassment in the specialty remains high 5 years after a previous study, with higher frequencies of recent experiences and continued low reporting rates.

At the Envision Summit 2025 in San Juan, Puerto Rico, Oleg Alekseev, MD, PhD, talked about difficulties in diagnosing inherited retinal degenerations due to mutations in over 300 different genes.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery

At the Envision Summit 2025 in San Juan, Puerto Rico, Ollya Fromal, MD, gave advice on how retina specialists can manage add-ons in their busy retina clinics.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria